TWI336698B - Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof - Google Patents

Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof Download PDF

Info

Publication number
TWI336698B
TWI336698B TW093108219A TW93108219A TWI336698B TW I336698 B TWI336698 B TW I336698B TW 093108219 A TW093108219 A TW 093108219A TW 93108219 A TW93108219 A TW 93108219A TW I336698 B TWI336698 B TW I336698B
Authority
TW
Taiwan
Prior art keywords
trifluoro
thiophene
sulfonamide
hydroxymethyl
etoac
Prior art date
Application number
TW093108219A
Other languages
English (en)
Chinese (zh)
Other versions
TW200504047A (en
Inventor
Anthony Frank Kreft
Lynn Resnick
Scott Christian Mayer
George Diamantidis
Derek Cecil Cole
Tingzhong Wang
Rocco John Galante
Molly Hoke
Boyd Lynn Harrison
Minsheng Zhang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200504047A publication Critical patent/TW200504047A/zh
Application granted granted Critical
Publication of TWI336698B publication Critical patent/TWI336698B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW093108219A 2003-03-31 2004-03-26 Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof TWI336698B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31

Publications (2)

Publication Number Publication Date
TW200504047A TW200504047A (en) 2005-02-01
TWI336698B true TWI336698B (en) 2011-02-01

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093108219A TWI336698B (en) 2003-03-31 2004-03-26 Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

Country Status (22)

Country Link
US (3) US7300951B2 (enExample)
EP (1) EP1608638A1 (enExample)
JP (1) JP2006522126A (enExample)
KR (1) KR20060002908A (enExample)
CN (2) CN1780829B (enExample)
AR (1) AR043940A1 (enExample)
AU (1) AU2004230844B2 (enExample)
BR (1) BRPI0408962A (enExample)
CA (1) CA2517155A1 (enExample)
CL (1) CL2004000647A1 (enExample)
CO (1) CO5640049A2 (enExample)
CR (1) CR7951A (enExample)
EC (1) ECSP056128A (enExample)
MX (1) MXPA05010368A (enExample)
NO (1) NO20054263L (enExample)
NZ (1) NZ542468A (enExample)
RU (1) RU2342374C2 (enExample)
SG (1) SG167669A1 (enExample)
TW (1) TWI336698B (enExample)
UA (1) UA82093C2 (enExample)
WO (1) WO2004092155A1 (enExample)
ZA (1) ZA200507896B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128491A1 (en) * 2000-12-13 2007-01-30 Wyeth Arqule Inc Heterocyclic sulfonamide inhibitors of beta amyloid production
NZ533603A (en) * 2001-12-20 2007-02-23 Bristol Myers Squibb Co Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome
RU2321394C2 (ru) * 2002-06-11 2008-04-10 Уайт Замещенные фенилсульфонамидные ингибиторы продуцирования бета-амилоида
RU2342374C2 (ru) * 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
PE20080169A1 (es) 2006-02-17 2008-04-11 Wyeth Corp Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
TW200732295A (en) * 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
BRPI0710470A2 (pt) * 2006-04-21 2011-08-16 Wyeth Corp métodos para preparar seletivamente um aminoálcool quiral e uma sulfonamida quiral
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
CL2008002058A1 (es) * 2007-07-16 2008-11-14 Wyeth Corp Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
WO2009012205A1 (en) * 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CL2009000019A1 (es) * 2008-01-11 2009-05-22 Wyeth Corp Compuestos derivados de aril sulfonamida que contienen o-sulfato u o-fosfato; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso como profarmacos para incrementar la semivida de circulacion de compuestos inhibidores de la produccion de beta-amiloide, utiles en el tratamiento del alzheimer y cancer.
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
US8992783B2 (en) 2008-09-05 2015-03-31 Max-Planck-Gessellschaft zur förderung der Wissenschaften e.V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223217B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
CA2792613C (en) * 2010-03-10 2016-06-28 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
WO2014039908A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP2987496B1 (en) 2013-04-19 2018-08-08 National University Corporation Okayama University Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CN109689071B (zh) 2016-05-16 2023-05-30 通用医疗公司 肺上皮工程中的人气道干细胞
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
KR920019763A (ko) 1991-04-26 1992-11-19 모리다 가즈라 아졸 화합물, 그의 제조방법 및 용도
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) * 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
IL110525A0 (en) 1993-08-09 1994-11-11 Lilly Co Eli Identification and use of protease inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
ATE377006T1 (de) * 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
CZ16899A3 (cs) 1996-07-22 1999-08-11 Monsanto Company Thiolsulfonamidové inhibitory metaloproteázy
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
JP2001519769A (ja) 1996-11-22 2001-10-23 エラン・ファーマシューティカルズ・インコーポレイテッド Ｎ―（アリール／ヘテロアリール）アミノ酸誘導体、その医薬組成物および該化合物を用いたβ―アミロイドペプチドの放出および／またはその合成を阻害する方法
DE19650196A1 (de) * 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
WO2000063194A1 (en) 1999-04-19 2000-10-26 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
WO2001027108A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
AU4086101A (en) 2000-03-20 2001-10-03 Merck Sharp & Dohme Sulphonamido-substituted bridged bicycloalkyl derivatives
SG128491A1 (en) * 2000-12-13 2007-01-30 Wyeth Arqule Inc Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) * 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
MXPA04005366A (es) 2001-12-11 2004-09-27 Wyeth Corp Produccion de alfa-aminoacidos de n-sulfonilo y alfa-aminoacidos quiralmente puros.
KR100921641B1 (ko) 2001-12-11 2009-10-14 와이어쓰 순수한 키랄성 β-아미노 알콜의 합성방법
RU2321394C2 (ru) 2002-06-11 2008-04-10 Уайт Замещенные фенилсульфонамидные ингибиторы продуцирования бета-амилоида
RU2342374C2 (ru) 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
CA2552558A1 (en) 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
TW200732295A (en) 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
PE20080169A1 (es) 2006-02-17 2008-04-11 Wyeth Corp Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
US7550629B2 (en) 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
BRPI0710470A2 (pt) 2006-04-21 2011-08-16 Wyeth Corp métodos para preparar seletivamente um aminoálcool quiral e uma sulfonamida quiral
US7476762B2 (en) 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
WO2009012205A1 (en) 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
CL2008002058A1 (es) 2007-07-16 2008-11-14 Wyeth Corp Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
PA8789801A1 (es) 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica

Also Published As

Publication number Publication date
JP2006522126A (ja) 2006-09-28
US7300951B2 (en) 2007-11-27
CA2517155A1 (en) 2004-10-28
CR7951A (es) 2008-10-29
TW200504047A (en) 2005-02-01
US20040198778A1 (en) 2004-10-07
RU2005133434A (ru) 2006-07-10
SG167669A1 (en) 2011-01-28
CO5640049A2 (es) 2006-05-31
US20090227667A1 (en) 2009-09-10
CN1780829A (zh) 2006-05-31
ZA200507896B (en) 2007-03-28
US7858658B2 (en) 2010-12-28
AU2004230844B2 (en) 2010-12-09
NZ542468A (en) 2009-01-31
RU2342374C2 (ru) 2008-12-27
BRPI0408962A (pt) 2006-04-04
US20070254929A1 (en) 2007-11-01
KR20060002908A (ko) 2006-01-09
CL2004000647A1 (es) 2005-02-04
WO2004092155A1 (en) 2004-10-28
AU2004230844A1 (en) 2004-10-28
ECSP056128A (es) 2006-03-01
UA82093C2 (uk) 2008-03-11
US7547725B2 (en) 2009-06-16
AR043940A1 (es) 2005-08-17
EP1608638A1 (en) 2005-12-28
CN1780829B (zh) 2010-12-29
NO20054263L (no) 2005-12-14
MXPA05010368A (es) 2005-11-17
NO20054263D0 (no) 2005-09-15
CN101274926A (zh) 2008-10-01

Similar Documents

Publication Publication Date Title
TWI336698B (en) Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7674813B2 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
CA2436526C (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
US7550629B2 (en) Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
JP4530849B2 (ja) βアミロイド産生の置換フェニルスルホンアミド阻害剤
CN1298386A (zh) 在肥胖症和其它病症的治疗中用作神经肽yy5受体配体的n－取代的氨基1,2,3,4－四氢化萘
JPS62228056A (ja) 化学的化合物
UA78021C2 (en) Thiazolidine carboxamide derivatives as modulators of prostaglandine f receptors
JP2010533723A (ja) βアミロイド生成の阻害剤
FR2758818A1 (fr) Derives 5-aroylnaphtalene a action anti-inflammatoire et analgesique, compositions pharmaceutiques les contenant, et procedes pour les utiliser et les preparer
JP2002506058A (ja) プロテインチロシンホスファターゼ（ｐｔｐアーゼ）のモジュレーター
TW200846322A (en) Heteroaryl amido lower carboxylic acid derivative

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees